News
FDA clears Nuvation's first product Ibtrozi, for lung cancer
Nuvation is set to launch its first commercial product after the FDA approved its ROS1 inhibitor Ibtrozi as a treatment for ROS1-positive lung cancer.
Sunday 22 June 2025
